Jaguar Health (JAGX) stock has increased by nearly 13% as of 10:15 a.m. EDT in this morning. The company yesterday released its 2020 financial results. 

Jaguar said the total Mytesi unit sales volume decreased 7% in the year 2020 over the year 2019 due to the COVID-19 pandemic played a role in this period. But Mytesi's net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019. The increase in product profits is a good thing. 

Jaguar Health is a commercial stage pharmaceuticals company. Its main product Mytesi has been approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.